SecBot SecBot
PRESS-RELEASE ·Filed Jun 10, 2026

CLDX

Celldex Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizondays Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

No new data or financial impact in this abstract-only announcement. Monitor EAACI presentations on June 14 for any substantive efficacy or safety readouts from the Phase 1 CDX-622 data or barzolvolimab long-term results; near-term price reaction likely muted unless unexpected positive/negative signals emerge.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$29.96
T+0 close · Jun 10, 2026 · via day close
Latest settled
+30.57%
T+60 · $39.12
Vs SPY
+26.75%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 11 $29.96entry
  2. T+1 · 5mo ago +4.37%α +3.83% · $31.27
  3. T+5 · 5mo ago +9.91%α +9.48% · $32.93
  4. T+20 · 4mo ago +30.11%α +28.22% · $38.98
  5. T+60 · 2mo ago +30.57%α +26.75% · $39.12
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Celldex announced three presentations at EAACI 2026: two flash talks on barzolvolimab's clinical profile in CSU and cold urticaria, plus a late-breaking poster on first-in-human Phase 1 results for CDX-622, a bispecific targeting TSLP and mast cells. This is a routine scientific conference update with no new efficacy or safety data disclosed, providing no material stock-moving catalyst.

Key Facts

  • Three presentations to be given at EAACI Annual Congress, June 12-15, 2026, in Istanbul, Türkiye
  • Two flash talks on barzolvolimab: one on long-term off-treatment angioedema improvement in CSU, another on psychometric validation of WI-NRS in cold urticaria
  • Late-breaking poster on Phase 1 first-in-human results of CDX-622 (bispecific targeting TSLP and mast cells via SCF) in healthy volunteers
  • Barzolvolimab is in Phase 3 studies for CSU and ColdU/SD, and Phase 2 studies for prurigo nodularis and atopic dermatitis

Financial Impact

No financial data disclosed; pipeline milestone update with no dollar amounts or revenue impact

Risk Factors

  • Barzolvolimab Phase 3 results may fail to replicate Phase 2 efficacy or safety
  • CDX-622 is early-stage (Phase 1); no guarantee of clinical benefit or regulatory path

Market Snapshot

Exchange
Nasdaq
Sector
In Vitro & In Vivo Diagnostic Substances
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3310079

Track record

21 reports on CLDX

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +19.96% at T+20 after the Jun 14, 2026 report. 4 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.97 Now $28.59 −1.31% settles Feb 12
  2. Nov 5, 202611d ago S-3ASR Neutral 3/10 Entry $29.87 Now $28.59 −4.29% settles Feb 4
  3. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $29.87 Now $28.59 −4.29% settles Feb 4
  4. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $29.71 Now $28.59 −3.77% settles Feb 1
  5. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $30.43 Now $28.59 −6.05% settles Jan 4
  6. Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
  7. Sep 22, 20267w ago 8-K Bullish 7/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
  8. Sep 22, 20267w ago Press Release Bullish 7/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
  9. Jun 14, 202622w ago Press Release Bearish 6/10 Entry $32.12 to $38.10 Now $28.59 +10.99% ▼ −18.62% −18.22% vs SPY
  10. Jun 14, 202622w ago Press Release Bullish 7/10 Entry $32.12 to $38.10 Now $28.59 −10.99% ▲ +18.62% +18.22% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Wed (11h 11m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 10, 2026